The Registered C¢)mpany Number is: 03059425 The Registered Charty Number is EThJknd & Wales 1046854 Scodand SC037596 Isle of Man 006171F ROY CASTLE LUNG CANCER FOUNDATION Roy Castle Lung Can￿r Foundation Report and Accounts 31 December 2023 11111111111 2￿12r2￿24 CC**ANIES TrIIXISE #195 Roy Castl• Lung Cancer Foundation Report and aceounts Contents Page Twstee5' Annual Report 2-23 Independent Audrtorfs reFQrt 2*27 consol￿ated Statement of Financial Actmties 28 Chanty only Stalement of Financial ActNil*S 29 Consolidated Balance sheet Charrty On￿ Balance Sheet 31 Consol￿at81 Cash Statement 32 Charity only Cash fiow siatement 33 Notes io the accounts 34-65 Roy Castl8 Lung Cancw Foundatlon Trustees. Annual Report for the year ended 31 Decernber 2023 Reference and administrative details Charity numbers.. Engknd & wa￿ 1046854 ScOt￿nd SC037596 Corr4)any number. 03059425 Registered Principal of￿.. Colton Ex¢h8nge Building Old Hall Street. Liverpool. L3 9LQ Diractors and Trustees The direGtor5 of the charitable company (thè Charity) are its trustees for the PUTP05e of charty law and throughout this report are collectNely referred to as ihe trustees. Tho trustses seTh*lng during the year and $ln¢e the year end were as follows: Chaimwn. Founder and President.. Treasurer and Vice Chair. Max Sleinberg CBE Professor Raymund J Donnelly MBE FRCS Euan Imrie James E Coulon David Gilligan {reswJned 27 February 20241 Anthony Coornbs Martin Grange (resigned 28 August 2024) Alison Lobb Atyson Chadw Mandee Lucas Alastsir Machray Cathy Brokenshire Emma O'Dowd lappoinled 27 February 20241 Jane Mullin {appoinled 28 August 20241 Donna Brenchley lappointed 28 AugU5I 2024) Company secretary Paula cha¢*1￿k Senior ManagementTeam Chief Executive.. Deputy Chief ExecutivelFinance Director & Director of Retail and Fundraising. DIr￿lor of Fundraising.. Medi¢al Director". Prevention, Information & Support.. Marketin9 & Communications.. Paula Chadwick Michael Grundy Jenny Lloyd Dr Jesme Fox Lorraine Dallas Rachel Avery Roy Castle Lung Cancer Foundath)n Trnstees. Annual Report for th• year end•d 31 DeceM￿r 2023 Professional Ad¥lsers Auditor. RSM UKAuéitLLP 14thFliJor 20 Cha￿1 Street L39AG Bankers". Barclays Bank plc LNerpcK)I City Businesscenlye. Lor(I Street L21TD Investment Ralhbones bankets PortofLNwFKK4 Bui￿rn9$ Pier L31 Soliators.. Braty%rsChaffeStreet Horton House Exchange H39S L23YL Jack%M Lees 44J45 Haryillon Square CH41 SAR Roy Castle Lung Can¢er Foundatlon Trustoes. Annual Report for tho year end8d 31 Decembw 2023 Foreword b the Chief ExKutlv• of R Castle Lun Canw Foundatio Welcome lo our Annual Trustees, Re[￿ on our actiwties during 2023. Ours is the only UK charity entirety dedicated lo helping anyone and everyone affected by all foms of lung Can￿r. It has two core functions". to save lives and support those INing wilh the disease. Each year, lung cancer kills almost 35.000 pewle in Ihe UK. which B more than the number of INes clainRd by breast. pancreatic and pros&*e Can￿rS combined. This is why our work is so vrtal. We seek to save livas by funding research, promoting ways to prevènt peop￿ from developing lung cancer. prirnarity by offering support for people seeking to stop using tobacco products, and developing high-quality Information resources Our research projects add to the store of infOrMat￿n on the development of lung cancer and help patients and their families beller undersland the disease and its impli¢*K)ns for their INes. Our Inforrnalion Centre creates and vpd*es bIg￿qualty collateral such a5 leaflets and online content, reviewed by pabents and supported by input from our research and prevention projects. We offer emotional and practical 5UPPX)rt through our nur5e-led helpline and online forum, and financial support through our patient grants. We represent lung cancer patients In the decision-makiny processes of both the Natsonal Inslilute for Hearth and Care EX￿llenCe {NICEI and the Scottish Medicines Consortium ISMCI, the bodies responsible for recommending the use of new medicines aryl Irealmenls within the NHS. Evidence from major clinical trials proves that ￿leening with Io•V-dose CT scans saves lives. We support NHS England's targeted lung health check programme. and throughout 2023 we were highly active in promoting and supporting this initiative. The evKlence is Gryslal4clear- scanning for lung Gancer saves lives ejnd improv&s outcomes Yet Screening is not a panacea, rt Gannot diagnose all cases of lung (ancer earty nor 15 It applicable lo everyone. As we aWays say, if you have lungs, you can get lung Can￿r. SD now we must do all we can to find and implement better ways lo Klentty lung can￿r al rts earliest 5tage5 of development In people for whom CT screening is not appropriate. This is our vis￿n for the future_ None of this woukj be possible withoul the tI￿leSS and semes$ efforts of our supporters and we thank them for all they do. The past three yèars have presented us with unPre￿dented chalknges. both in lems of day-to4ay operations and in raising funds to support ourwork. Yet there are also strong reasons for optimism We have witnessed significant advances in lung Car￿er care ar￿ pio¥i5ion in the last decade. and. if anything. the rate of Ih8se advances seems to be increasin9. We are abS￿utelY dedicated to achieving further improvements as we fimity bdieve that everyone affected by lung ￿nCer should be able to EXPECT BETTER. Paula Chadwick Chief Executive Roy Castle Lung Cancgr Foundation Trustees. Annual Report for the y•ar ended 31 0￿mber 2023 Ob'ectives and a iviti The Roy Castle Lung Cancer FOundat￿n c￿panY Nurrt)er 03059425 (the Foundation) is a company limited by guarantee governed by its Memorandum and Artth of Assc¢￿tIOn Past arnendecl 31st January 2011. The company L% registered a5 a chanty with the Charty Cornmission in England and Wa1é5110468541. the Office of the Scottish Charity Regulalor ISC037596) aTrJ the IrKlex Df Charite5 on the IS￿ ol Man112711. We exist for the benefit of lun9 cancer patients. and all aflected by the disease. By securing donations. legacies and sponsot5hip. the ch*rty caFt rnake materkql Improv￿rIen18 for patients. their familie8 and thase who IcM)k after them. We have establishéd the charity as the UK'S pnmary support resource for all diagnosed with lung ¢anc8r, and their familie5 and rarers. We aim to bethe representative 'voice' of lung cancer patients in 811 areas of health care polw and provision and offerfirst-C￿￿ information and 5UPPOrt services. ur Tha ¢harity has a dual focus.. savin9 lives and $UFVJrting pewe I￿7ng ￿th lung cancer To do this. we promote and fund research tnto the causes. prevention. and I￿atMent of lung cancer. we develop health piomothon programFnes aimed at preventin9 the onsel of lung cancer. and we offw practical support to improve the quality of lrfe of patEnts and their ￿laINes. During 2023 continued en7phasis was placed on contrib(rting to the successful IMp￿entst￿n and promotion of ihe NHS Englahd Targeted Lung Health Check ITLHCI prDgTamme. This has contribuled 3KJnTticarty Io ihe formation ofthe nation81 lung cancer screening prc*Jiamme ambitKJn of the NHS Long Temi Plan to irnprove eaTty diagnosis stsmval foT people wth cancer In raising new money and by careful management of our existing frjnds. the eharity provides È public benefit by addressing unmet needs. We do this by making grants to serve lung cancer patients and their families receiving servtss, by fvrKling research, and by wr asxKiated Informal￿n. support. and p￿ventIOn setvices. Thè trvstees confim that they have pard due ward to the public benefrt guidan¢e published by the Charity Commission and OffKe ol the Scottish Charity Regulator. The Foundation ￿ferS to the Publ￿ benefit guidance when r8vi¢wing and settiTrJ ts aim5 and ots'eclwe5 and in fvlure planning. Whèn considering where to focus our attention. oui ￿rpOrate trustees, board and particularly the rnembers of the charrty's research funding committee have regard to the Charity C¢xnm1ss￿n's guidart¢e on public benefit and what this means for our charity. chi nd Perf miance RCLCF-funded Research Policy on R*search Grant Making Thg charity operates a rgbu5t applicalL￿ process to ènsu￿ we only fund the very best saence. Applications are received an open grant applicat¥Jn programme, independentty peer*reviewed by our own grants committe& then externally peer-reviewed by leading experts in the relevant field priorto funding being recommended. Oue to the Impacf of the COVID-19 pandemic we suspended our formal Research Grants program in 2020. We resumed accepting 5ubrnis5ions in 2022 wrth a VEW to research proiects commencing in 2023. However. having ￿te1Ved few applications, we awarded onty one new Research Grant. to Dr Catheriné Htsnshall of Oxford Brookes Universty. Roy Castle Lung Cancer Foundation Trustee5' Annual Report fof tha year •nd•d 31 Decembgr 2023 The project. rthy underytsy, aims to look al the barriers to lung cancer patients tsking part in clinical trials and the OPFK)rtuniliÈs for encouraging part1cv￿On. As the research climate remain5 uncertain. we havè C￿centrated funding to expand our Clinical Resèarch Fellowships. including the introduction of th8 James Brokenshire Clinical Researth Fellowship. The first r ReSe0￿h Fell¢)ws will start in January 2025. Nottingham Univ•rsity RCLCF Clinical Research Fellowship Dr Helen Morgan is the third CRF fvnd￿ by RCLCF at Nottingham. Dufjng 2023 her work included. DECLINE Study {Decisions against curative treatment for lung cancer in eligible patients). to examine reasons why some peop￿ wth lung cancer for whi¢h curative treatment is a viabl8 oplion decide against having such twlment Rapld Cancer Release Dataset A series of papers analysing the impact of COVID-19 on lung cancer treatmenis and survival in the Unrted KiThJd¢)m during 2020 Articles published.. The Impact of COVID-19 on Lur¥J Cancer Incidence in England.. Analysis of the National Lung Cancer Audit 2019 and 2020 Rap￿ Can￿r Regislralion Datasets. Gysling S. Morgan H, Ifesemen OS. West D. Conibear J, Navani N, O'Dowd EL. Baldwin OR. Humes D. Hubbard R. Chest. 2023 Jun,'163161'.159¥1607. doi.. 10.101611.¢hest 2023 01 008 Impact of thè SARS-CoV-2 pandemic on lung cancer Survival in England.. an anatysis of the rapid can￿r registration dataset. Morgan H, Gysling S, Navani N, 881(Jwin D. Hubbard R. O'Dowd E. Thorax. 2023 Dec 15",79{11."8345. doi.. 10.1136nhorax-2022-219593. Thesis and PhD. Dr Morgan I￿￿sSed on ffinishiThJ and submiéling her thesis for Doctor of Philosophy with the Universty ol Nottingham. We are pleased lo say this was awarded in April 2024. As well as the DECLINE study, her compkned research prcie¢ts from this peric¥J of study include". D8Jfining cure in non-small cell lung Can￿1. The impact of COVIt>19 on lung can￿r treatment and survival in the UK. 90-day nK)rtalty outcomes followng thoracic surgery fvr lung cancer in England. Further detsils of all our ￿Sea{ch can be found on the charity's website.. roycastle.orglresearch. F Polic Work in 2023 Key policy areas have been to woth wich ¢lini¢ians. patients. health policy, regulatory and olhers lo ensure- Focu5 on working t(y•Rrds deleclion of lung can￿r Implementstion of the National Optimal Lung Cancer Pathway B￿marker testing tumaround lime of weeks The charity provides the secretarial f￿ the Lung Cancer Clinical Expert Group ICEG). This is an independent gTOUP of multidisclplinary experts frcxm a¢ross lurig cancer specialilies. patients, charities and professlonal socielieslbodies with an Interest In lung canr£r. It provi¢Jes expert adw¢e on clinical issues in thoracic malignancEs, particuLHrty in areas of heahh pdicy and strategy. All four devolved nations of the UK are represented. Roy Castle Lung Cancer Foundation Truste•s' Annual Rep)rt for the year ended 31 December 2023 During 2023, CEG work included the updating of the National Opkn'mal Lung Caft￿r Pathway and associated Commissioning Guidance. The CEG also made Submissi￿ to the Health Select Ccffimrttee's Future Cancer inquiry. The charrty has continued to weik as a cOnsurt￿ to NICE (England) and other kdies to ensure promtsing new lung cancer Iherapies are availab￿ in the NHS. The National Lung Cancer Audit INCLAI began in 2004. and SIr￿è 2022 the contract for its productK)n has been held by th¢ Royal Coll￿e of Surgeons. The chanty continued to support the wtsrk ofthe NLCA during 2023 and rnaintained both Its Mèrnbe￿h1p of the NLCA Board and rts Clinical Advisory function We also provided input to the Get Data Out IGDOI Lung Can￿r Inrtiaiwe and the Lung ￿nCer e-Atlas initiative., both in England. Thè charity ￿tains its focus on the earfEr detectKJn of lung ean¢¢r. Work in this field during 2023 included supporting the Lung Cancer Screening and Targeted Lung HeaKh ChedK Program (Englandl. In 2019 NHS England embatmed on the Targeted Lun9 Hearth Check PrograFn ITLHCI. Roll out of this continu￿. We assist this work in an advisory role, providing expertise in cornmun￿at￿)nS and supporting local communty engagernent. In March 2022, RCLCF convened an expert meeting on lung cancer scrvning in Leeds. 40 experts attended. A meeting report is available on the RCLCF website. Outpui ol the meeting resulted in a publication during 2023" 0'Dowd. F. L., Lee, R. W.. al. (20231. "Definw the road map to a UK natitMal lung cancersc￿￿11 pr(￿r￿m. ' We have continued to provKle input to the NHSE Earty Detection Task and Finish Group, which provKles oversight of the TLHC proJram and to the NHSE Advisory Group on Lung Cancer Screening. Screening is key to improving earty dÉteCt￿n of lurrtJ cancer, by mak¥ng the diagnos15 before symptom5 appear. However. the majority ol eases will still be diagnosed when symptom5 are appa￿nI. In MarGh 2C)23. we convened a meeting of expert5 to discuss this top￿. The purpose of the meeting was to explore barriers and Issues around late diagnosis in symptornatic lung ￿￿eT. A report. including recommendations, is a¥ailable on the RCLCF website. A PaFEr is beirwJ prepared f¢y wbrnission to journal publication. Throughout 2023, the charity continued to work wilh the wider healthcare community. ensuriny the lung ¢ancer,vo￿e'. Work included mernber5hip of the Ta5kloTce for Lung Health," Lè55 Survivable Cance Ta5kforce. One Cancer Voice. grcMJp. and the UK Lung Cancer Coalition. Their Irnp8Ct Report. 'Driving Improvements in UK Lung Canr*r Care- The Power of Working Tcgetherf was published In November 2023. Global Lun Cancer Coalilion GLCC The GLCC nurnber$ 41 organisat*)ns from 29 nations WOrlD￿lde. RCLCF provides rts Secretariat. Members nefv4ork online at the Annual Meeting prk)r to the Intemational Ass(Kiation for Ihe Study gf Lung Cancer IIASLC} Wortd Gongress on Lung Cancer. Since 2003. the GLCC has hosted symposia, at the invitation of the IASLC. In 2023 GLCC ￿rSOnnel shared details of research wa symp05k4. Spoken or poster presentations. Other key GLCC projects carried in 2023" The fourth Intemational Consumer Poll into public awareness of lung caneer and stigma 8ssttiated with the cjisease. repeating our polls of 2010. 2013 and 2017. In 2023, we also inquired into attiludes towards lung cancer screening. The fourth international p*ient experience suryey to create intelligence and insKJhts into their expenence of diagnosis, treatmenl and care. This suNey wort( wa5 presented at the IASLC Worhl Lung Cancer Conference in September 2023. Coping bwth Lung Cancér Prqect. The f￿u5 for this ongoing Pfoject is to explore the question of "what helped you get through lung can￿(?. In 2023 we convened focus groups to better understand what types ol se￿1￿ and support member organFAtions offer. what challenges they face. and ttow lo overcome them. Roy Castle Lung Cancer Foundatk>n Trustee$. Annual Report for the year ended 31 Decernber 2023 Our Lung Cancer Screening Resources M1w￿lIe was expanded to include participant information on Pulmonary Nodule management Communicating the need for surveilkgnce of pulmonary nodules, found through screening, is often drffKurt. so we offer examples of 'best practice, leaflets frorn screening prograrns already in place. We updated and refreshed our online interacfve Lung Cancer &4tlas, making it easier lo download and us8 data for reports and presentations. The GLCC cornmissioned the Institute of Cancer Poly IICP) to update its report rnapping published lung cancer rèsearch across the globe. assessing the wortdwde impact of the pandemic on research. We published more new factsheets and offer a series of awareness leafflets available in 161onguages. Key partnerships in¢liJde Ihe Lung Arnbition Allian￿ and the Gkjbal Can￿r Coalrtions Network. Lun Cancer Informalion & Su ort Serv Our services are designed to promote eaty detection of lung can￿r and provide relevant information and support to those affected by lung canc￿. Infomiation During the course of the year. we received 820 requests for infomwl?on materials. We distributed 10,735 'Answering your queslions, packs. 21.214 treatment leaflet5 and 8,557 publications on awareness, living with lung cancer. and the diagnost￿ process. Financial assistsnce We provided grants to 597 individuals wrth a lung cancer diagnosis. A total of £71,893 of charity funds were distributed VK? the grant servic&. Support services An average of 38 people (those with a lung cancer diagnosis or caring for someone with lung eancerl receivèd support via our Keep in TouGh service ea¢h month. Support was delivered by three member5 of 51aff and equated to 221 hours of wnta¢t. Our Ask the Nurse Servi￿ responded to 1199 nthv enquiries phone, email and online requests. A further 160 ￿peat enquiries We￿ also received. 14°h of erNuirie5 came from people concerned about symptoms. 46°% from patients, 29% from careis. 5% from heath Care Professionals and 6ts￿ from other conl&ls. Communications and Marketin Resources were dmded between provKling support to other depart￿￿nts and delivering the charity'5 core obie¢lives. Chief among these has been our focus on early deteGtion of lung cancer, specthcally, the NHS England Targeted Lung Heakh Check (fLHC} pr￿313mMe. Targeted Lung Health Check Programme l National Lung Cancer Screening Programme for England We continued lo support both the natior7al NHSE team and Cancer Alliances ICAS) to drive uptake of this programme. To this end. in March, we launched the first phase of our TLHC awareness campaign, commissioned by NHSE aftèr feedback suggested many did not attend lung heamh CheC￿S because they felt well and had no symptoms Our primary aim was to highlsyht the often-asymptomats"c nature of eaty stage IuAg cancer and to encourage people to attend even rf they felt well. We prodU￿d a swies of marketing assets for programmes lo utilise, as well as a campaign t￿Ikit. Facebook ad set and reporting guides and a suggested activity delivery scheduk. Roy Castle Lung Cancer Foundation Trustees. Annual Report for the year •nded 31 D¢¢emb¢r 2023 A press release issued by NHSE highlighted the chanty's colLaboratk)n wrth the campaign and included a quote from Chief Executive Pauk ChadvAck. This was p￿ked up by a number of media out￿1$. including the Guardkan. In June, the UK governffEnt announced the implementatK)n of a national lung cancer screening programme for England. The charity was asked ty the Oepartment of Heakh and &xial Care to prowde a comment for inclusion in a press rekase about the announcement, to acc(￿npanY quoles from Ithenl Prime Minister Rishi Sunak, Ithenl Secrelary of State for Health. Steve Barcby. and Chief Executive of NHS England INHSEI Amanda Prrtchard. Sevèral publications. including The Guardian and The Daily Mirror. published this. The charity was also intemewed on BBC News and Channel 5 News. On 1st Aijgust (World Lung Can¢er Dayl. w* ctssigned an open lelter a¢Jdressed to the Welsh Assernbty Minister for HeaKh and Social Services. Eluned Morgan MS. ¢alling for lung ¢ancef screening in Wales,. this was covered by Wales Online. Throughout the year, we continued our support forthe folkjwing TLHC programmes, providing mad(eting andlor community engagement support in eleven Ic¢ations nationwide. In Liverpwl. Bimiingham. South Sefton and St Helens. we ran soual medo ads which, c￿￿Ct￿elY generated a 10.5V/* click through rate and secured bxal rned￿ coverage. Lung Cancer Awarèness Campaign: Bè Unforgettable In Novernber. we launched our Be Unforgettable carnpa￿n. It asmed to chalknge three primary misconceptions around lung cancer- nihilistic perceptions, patient stereotypes. and symptom confusionlcrossover- which can delay d￿n0515. The campaign wa5 fflultrf3ceted and included the following activity.. The Let's Talk Lung Cancer Roadshow. in partnership with NHSE." 10 events In Hull. Middlesbrough, Vvarrington. Lei¢ester. London, Boumemouth. Rochdale. Morecambe, Leeds and Sheffield. BBC One Moming Live ran a 4-minute segment on lung cancer. narn￿hecked the charity and displayed ar image of the MegaLungs and campatgTh banner from Ihe Hull event. Targeted so¢ial media ad Gampaign We ran two targeted ad campaigns on FateLy￿{. targeting a hKJher risk audience (based on age, links to smoking and selected occupations} and a lthvef rBk audience (based on agel. Other activity- Radio Day: Segment picked up by 163 stalions. resuhing in over 20 hours of airtime to a listenership of 51 million (see LCAM 2023- Media Rep(Hl IRCLCFJ) Partnership wilh South East Cancer Alliance- Out of HorrE a(fvert15ing on bu5 Stops. tube and train stalions and gym5. plus online content. Avrnreness packs: Dislnbulion of appro¥. 4Q) ¢ampaKJn ￿kS to Lun9 Cancer Nurse Specialsts. CICS and supporters. Transatlantlc panel.. Go2 Foundation for Lung Can￿r liwng r￿M session, discussing lung cancer stigma around the world. Wèstminstsr èvent.. Co-hosting a parfAmentary event wrth MSD. where CEO Paula Cha￿l¢k a¢Jdressed MPS on the next steps for lung cancer. Roy Castle Lung Cancer Foundatlon Trustees. Annual Rèport for the y￿r ènded 31 December 2023 Levs Talk About Lung Cancer POd￿t After the success of the Lung CancerAwareness Month pcthast s￿CIalS, we Off￿131ty launched the Let's Talk About Lung Cancer podcast at the beginning of 2023. We produced 23 ep15r>Je5 which generated 7512 plays and accnJ8d 178 subscribers I followers. Insplrg Magazlne The annual Inspire magazine, wrth latest lung Cancer infom)ation and charity updates. was produced in-house and disthbuted to all mailable wam) supporters {93111. In addil*Jn to this, over 30C(I copies were dispatched to lung cancer nurses and cancer Informati￿ centres. Impad Report During 2023, our latest Impact Report. outJiniThJ our impact achievements arKI aetiwty durin9 in 20218nd 2022 was published. World Cancer Day On 4 February, we ran our World Cancer Day campaign. I￿usIng on the pr(ure55 that ha5 been madè wrthin lung Cancer. Patlent Inforniation Updating existing patient infomiatb)n ttDnal ccfftpany to rai%e funds for chantable purposes The cuwany resum fLYthe year was a profit d£141,86812022'. £122.287 prafrtl before a gift aKI payI￿tIO the Chanty Of£141,￿ {2ry22". £122.287). Cut Filrns Ltd was established on 13 Juty 2010. ￿￿InalY as a trading subwdiary of Cut Films Project Ltd. n8rsh¥p transferred to the Roy cast￿ Lur¥J Cancer F¢)undatk)n in Noverrt)w2018. The compary result forthe year was a bss crf£1.191 12022." £7,8￿ k6sl Therewere rKJ gfft aid payrrEnts to the charity relaong to 2023 12022.. £nill. Financial evEw Thè charity, as a group, made a defiut d(Yry 21Y23 of£644.451 (2022.. £80,345 deficrtl. Thts was a dtsapwntir¥J resum dnven by the econcmc environnpnt reSU￿rg fr￿7 the war in Ukraine and rts impact on the Gost of liwng. k)Ilowing so closety on from the ￿npact L* CovK119 ptes5ure on staffing costs. me and fundi Total income for the charity decre8sed to £4.971.709 fr*the year12Q2." t5,3C6.C661 foikywing the pte5sure on otjr retail operatKsn and of our ￿nd￿sing actmbes. Legacy Incr￿ synfv• *re8sed in 2023 falling to a more usual kvel £351.36912022.. £902,102) follovAng a s￿taCuL￿rYear in 2C122. Li ￿pe￿5 to h3¥e Tel￿Unded back up a3ain in 2024 based on lateFt fvJvres. Trust ineome also feN slightty to £113.LKKJ12022'. £146.3591. Other voluntary d￿t￿)n5 rose to £423.394 in 202312022. £393.6871. HNever. In Mernoriam donat￿nS fell Slightly to É180.77012022." f230.1411. However. this of per￿al. Ind￿idual SUpp￿t remains a kay income stream forth8 chanty and ￿ a tèstament tot￿ prk* it take5 in great C￿ and a personal tc¥Jch. SFM)nsorship inwe inrnwl slightty in 202310 £503.539.12022." £487.5111. Tfade wa5 tough lor Retail during all of2023 and rt Wds undoubtabty aff&Xed by the ￿t￿0Vid 19 enwronment and 5rtuatiLiii was fvrther nnp3Cted by the cc6t-014rtriThJ cxw folk￿rg the start of the war in Ukrwne. Retail increased its saks and generated a gross profft of £ 2.233.14512022. £2.165.562). end the net results Ihe year was 8 profit of£80.538. wh￿h was an tmprovemenl on Ihe pre¥￿u9 year12022." £14.995 k>ssl. Gft aid ¢Jn donations for 2023 rosè to £247.671 (2022. £228.4711. nditu Ovèrall expenditu￿ for the yearwas tS.636.21612022" £5,305 459), tefjeLb"ng btsth infftased bul a signrficant p￿sUreS on costs folknwng tspKJ irKrease in inflat￿n and the wdges bill. Totsl charit*Jle expwKliture ts 2023 was £2.103,￿2412o22." £1.937.5861. and research expenditu￿ was £1,436.874 in 202312022 £1.1%.7231. nVeSt￿￿t The Charity hokJs £e69,78312022". £873.&S41 in listeLI invesb* The charty's Investsnents generated an income of£23,271 in the year {2022.' £28,352). The investsTrnls gener*ed a smJl 8nN)unl d gr￿th during 2023 and ended the yearwith a £20,056 r￿t gain ￿ invesfftnts12022. £80.952 lossl The rnain reason for the redwknon in the value of the ptsrtfdio during 2023 has been the need to SUFplement working caprtal whdst cash froFn protraded legacy sd1lern￿tsWere Teali8ed. tlv haNt sTrnce bagun b corne thTwgh in 2024 17 Roy Castl• Lung Cancer Foundatlon Trustees. Annual Report lor the year ended 31 December 2023 Rathbones, an indwndent st(xkbr(*er, ffwwJes the invesbrents within defin￿1 areas. The stskbrcJ¢ers have been instructed to invest in tobaCc(Tr￿ lated conwanw &)d other s￿la1￿ unac£eptable wnpan*s. The current inVekn￿nt polw of the tsuste89 is to hc4d a W prCP)rti￿ of surrAus assets of the F(xJnd*ion in cash and near-cash to ensure a *abk platform fry Organisat*￿'s ¢￿t￿L￿d *Triitw. R8serves The Iruslee5 have adopted a reserves Fk)Iy whth tw c￿s*Jer 4)prcvr￿te to ensure the COnb"n￿ abilty of the FourKlation to meet its objectives ¥*d the specfft nature of (**lvJabons in relaksn to kmg.lerm research in the fom of grants. The Charity n￿nItorS lés reserves polry based on the ctJligat*yi$ ncrfgj above ccmpared to free resejves and overall Ivjuid assets. al Free reserves The level of Free Reserves. as defined by Charty C(ytmissK)n. are the unrestricted funds available f¢x nding and are therefcxe Iraditionalty c2kulated by lakThig the total unrestrLlal funds ofthe chanty and deducting any baances not avaikble for SFending. As all investments held by the charity are liquid and readity onverted immediatety into cash to spend, these have been indL*Jed in the c*ulation for the ChantEs Reserves. PDlicy. The charty's free reserves are therefore unrestricted reserves less tangible fixed assets. The level of fr* reserves hekj (ak)j￿￿￿ on this basis are a negalwe £15,576 Irestat&l 2(Y22". £394,234 P¢6ilwe) To hold suffi¢Ent fvnds to cover all future outstaTrJing research grant c&I￿at￿ns. to secure the safety of our wlal research work togetherwith:_ three rrKJnths general n0rpselr.firwK￿g charty experKlrture The charity's requi￿ reseNes ￿ £457.040 {2022: £518,250). the ¢harity did rK)t al Ihe yearend sulficEnt free ￿serveS to meel the required levd calculaled. This was in part due to several, ￿rge, long standing outstanding legacy payments depressir¥J the cash posrtion and in part due to the overall poor financral perfcrfmance in 2023. Hcmever the charity. stnKture and staled purFttses does mean that the tharity's restricted fvnds effectively n￿et many of the c*lvJatK)ns and costs of the Gharty noted above. The Charity's pogtKJn Sin￿ the year end has dr￿￿t￿lty irwrov8d bcAh in temis oftha cash posthon with r8￿lpt of sèvèral of the addit￿￿31 and outstanding legacEs and rts overall finanaal perforn￿n￿ which to October 2024 created a surplus of £112k. The tevel ofFree reserves as at 31 Octcthr 2024 would be £251,566 much closer lo the required level of £457,040 To refle(a the true purI￿e ofthe Chartys restrided reserves and as a S￿nd control the trustees also monitor the level ofcash aThJ Investments held 4ain$t a Icryer-temi VEW oflhe ¢tsrtls potents.al cOr￿trnents, and the Value of the company lThis is purety an inlernal measure). To hc4d Su￿lent funds lo eover all future outstanding ￿SearCh grant obl￿at￿￿$, to Secu￿ trt safety of ourvitsl ￿earCh work three rTh)nlhs genwal non-self-financing Gharty e￿nditUre a reasonable proMsKJn for any potenlk41 ￿lundan￿*S based on IW of SerV￿e the full outstsnding of non-sew￿na￿lng prcyty costs On the above basis, the resources required are CalcUL￿ as £1,025,05812tr22. £899.2741 and the chanty currently hehj £709.640 in cash and ￿VestMents at the erKI of 202312022: £1,084,714), the overJl balance sheet value less the value of fixed assets was £507,65212tr22". £1.139.7661. Again th￿ measure has drarnat￿lty improv*1 sinr* yearend and currenty the values of the overall balan IO¢tthrl sheet value less ￿ walue of fixed assets is ￿TrentlY £648k closer to the requir&J figure. A key pmrity tor the charity is to rebuild the of reserves to rrEel ts pcwever. as much of the chanties kjng temi thligalx￿s in respect of research, patient support, GLCC projects and other chairtabk activi￿e$. whjch form part of the core of the chanty's actiwtie5, are Wtthin the rernrt of much of the restrthd lunds whilst thi5 i8 seen as an issue it 15 not seen as unsum)ountable and again the ￿$￿￿)n has improved during 2024. The Trustees have therefore conclLthd that the charty and group have sufficient funds to be able to continue in expster￿ for the foresaeable future and thus c£ntinue to adcyt ihe going basis of accounting in p￿paring the financial ststernenls_ en The trustees have a risk managemerrt strategy to assess business rtsks and to mibjate those risks. The strategy compr￿e$.. regular wew of Tisk5 the ChaTty troy I￿. PTKJribsir¥J in terms of potenknal impact and likeh'hoL of occurrence and systems contrL4s, intemd cheL*s, and prc￿edUreS to mrtgate risks KJentrfEd in the plan and to msnimise the pclential Iiipacl on Ine Charity. The Irustees have hdentrfied the four prinupal iisksto as 11 signrficant decrease in irTrcon 21 r￿lUced wbliG furtdra￿lng and a change in retail trer¥Js 31 staff recruit￿￿& and retenlKn and 41 fvjrther pressure w the wst strudure frcm o)st oflMr*J iises. 19 Roy Castle Lung Can￿r Foyndatlon Trusto&s' Annual Report for the year ended 31 December 2023 The Charity bdieve5 that these busine55 rtsks ￿Ul￿ be effthely rronageé by restruL#uring existing resources and rnaintwniNJ apprcpriate accessibk cash reserves. A lie￿1 management strukaure is bemg devek)ped to allthy intemal staff prcgression a dear patt￿aY to wh￿h t{y￿er with investment in training and 8pproprde rern￿nerati￿ B ￿e￿gned to wnwove *aff retent1￿ and rgyuitmenl. Events on the Sca￿ of the ￿d19 pandem￿ or the RussHTrLknine war had ncrt been erbvisaged prior to 2020 but the above actions have prov&J adequate to date at trÈ tme of the trustees. report in 8￿cessfUllY man&aing the situalKJn and ensuring the future of the charty and the refl￿d in subsequent llsk regi5ter5. Plans for the Futurè. Screenin The Targeted Lung Health Check proJramrne in EThJland post pandem￿ is making a sFJnrfKanl imp￿1 on lung cancer wrth 3*5 diagnosis s￿ce ils introdwt*)n {Oct 22) to March 2024 and a signrficanl switch lo earlier stage diagnose wrth the obvious beneffts in prourL>sis. National ProwaThm* Metrics actmty frcffl prcgramme start up until eTrJ of VArch 2(r24 Invltes sent 1.591.798 Lung Health Checks attended 713,931 Baseline Follow up Total Lung cancers diagnosed stage 1 313.672 110.723 424,395 3,965 620/0 13./0 130 90 Scans Stage 3 Totsl inciderrtal findirwJs 185.081 Corcmary caCffiCat￿n 140,801 Incldental findings Ernphysema 57.078 Sum of all other incKlental findiThJs (rK)t incI￿￿1ng CAClemKthysema) 72.T14 We continue to inve5t*Jate hcw we can atso suppryt Lung He*th pik)t5 n Scot&nd, Wale5 and Northem Ireland. the potential impact of the TLHC pYogran¥ne is peth•s the single ffM)St thnportanl step forward for the lung Cancer ccmmunty at the pwnt tyne and the ch*ity is detemined to make it a success. We will put wh*ever resources we can ￿h1ThJ li and the successfvl ryknrrtalion of the nalKJnal sueening prc*3ramme as announced duriry 2023 and expthj to be in fv by 2029 20 Roy Castle Lung Canctr Foundation Trustees. Annual Report for the year gnded 31 Deeèmber 2023 Research [￿ring 2022. we re45tabli5hed lung cancer ￿search programrre. Hry4sEver. the re$F￿Se lo the call for appliixttons was low and we ￿eNed a similar re¥rf)nse ￿ 2023 Clearly, postJtstts (walKJn wll be streamlined. 21 Roy Castlo Lung Cancer Foundation Trustses. Annual Report for the year ended 31 December 2023 Statement of trustees. responslbllllles The trustees I￿0 are also (rfT￿ Roy Castk Lung Caw Fc￿ndal￿￿ purposes of ctsrpany lawl are responsibk for prepariro the TrUSt￿S. Re￿t and the financial stateft￿nts in accordance applicabl8 law and United Kingdom Accounting Standards IUnrt&J ￿"ngd(yn Generalty Accepted Accounting PraCt￿e). Company law requires the trustees to preparp $tatwnents for each financi81 year vthich gwe a true and fair view ofthe state of affairs of the chafitsble cryny arKI the group and of the incoming resources and applieatF)n of ￿SourCes. induding the Irhccfft art(J expwKJrtufy. of the chantabk gr￿P for that peric*J. In pwaring tkwè financkql statements, the trustees are requirad to." Salect Suit￿le xcountiThJ poI￿leS and Ihen ap*rf cc￿s15tenty,. observe the rrEthc•J5 and principles in the Charths SORP" make judgments and estimates that *e reasonab￿ and pnmjent," stale bvhether applicab￿ UK Acccwnting S￿￿18rd$ have been fdkhv&l. subj&t lo any material departures disclosed and extAa'ned in Ihe fina￿￿￿1 Staten￿nts.. prepare the financaal ststements cffl the'going concem. ba￿S unless tt is in¥propriate lo presume that the charrtable group and corryry wll conlinue in busine5S. The Iruslees are ￿5F4)nsib￿ for keeping *eq￿e Koxxjnting recorts that wth reasonable accurdGy al any time the financial pos((h?n of the ¢haritabk conpany and group and enable them lo ensure that the financial State￿nts comply with th8 compan￿ Ad 21x6. the charit￿s and Trustee Investment {Scotland) Act 2005 and the Charities Acccyjnts (Scotlandl RegulatK)ns la5 amended). They are also responsible for safeguarding the assets of the charrtabie company and the group and tjence for taking reasonable 5tep5 for the prevention and etection offraud arKI other irrgjulartrs. The trustees are responsible for the rna1ntenan￿ aTrJ integrty of the CO￿Tate and financkal irrformation i￿luded on the websrte (http'.1h￿v.rOYca$tIe.or9I. LegisL7lpM in the Unrted KirrfJdc¥n governing Ihe preparalNJn and disseminab.on of financial statements may dIfferfr￿ legi5L8tK)n in other jun5dLtK)ns Statsm&nt as to dixlosure of infornulion lo athlitors The trustees who were in office on thè dale ofapproval ofthese finanaal statements have ccfjfimed, as far as they are aware, that there is no relevant audit infwna1￿ (rfwhth the auditor5 are unaware Each of the trust￿ have confirrned that they have taken all the sleps that they ought lo have taken as Ifustees in order to make Ihemsefves awa￿ ofany relev8nl audrt infornBtion and to esta)lish V)at it has C￿MUn￿￿ted to the audi(ors. Audiiors The auditors. RSM UK Audi( LLP, have ind￿ted trwrwillingness to LY)ntinue in ¢¥fi￿. Staff We would like to pay tribute lo the staff of the FourKlai*)n wtro continue to CAJnsider*•le enthusiasm and corrfflitmenl. Partnws and supporters we%￿uld liketo rerL)rd a s1￿erethar￿s to all Ourpartn￿5 supp)rter5wh) have helped the Charrty in any way this year. 22 Roy Castlg Lung Canc•r Foundation Trustees. Annual Repjrt for the year ended 31 December 2023 em Small Cownpony Provisior This report has been p￿Pared in acccKdarKe th¢ pr(M6ions appkcable for corryanEs eTrtit￿ to the small cixnpanies eXewYt￿. By c*der of the trustees guan Imri6 Euan Imrie Treasurer and Vic• Chair Date.. 13 Decernber 2024 23 Roy Castle Lung Cancer Foundallon INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES AND IIJEMBERS OF ROY CASTLE LUNG CANCER FOUNDATION Oplnlon We have audited the financial stalements ol Roy Castle LuThJ Cancer Foundation the 'parent charitabbe company, and its subsidiaries {the 'group'l for the year ended 31 D￿rnber 2023 whiGh comprise the consolidated and Parent Charitable Company Statement of Financial Ath"vities linduding Income and Expenditure Account). the consolid*ed and Parent charitab￿ Company Balance Sheets. the consolidated and Parent Charitable Corryjany Cash Flow Statements and noles to the financial statements. including significant accounting polieies. The financial ￿p0￿"n9 frarrthork that has been applied in their preparation is applicable law and Unitèd Kingdom AccountirvJ Standards. induding FRS 102 "The Financial Reporting Standard applicable in the VK and Republic of Irdan¢f (United Kingdom Generalty Accepted Accounting PraCt￿e). In our opinion the financial slalements". give a true and fair view of the $lale of Ihe group's and the parent charrtabk company's affairs as a131 December 2023". and of the group's and the parent chariiable company's incoming resoLErces and application of resources, including their Income and expenditure, for the year then ended,. have been propety prepared in accordance with United Kingdom Generalty AC￿pted Accounting Practi￿., and have been prepared In accordance with the Comp8n*s Act 20C6, the Charities Act 2011, the Charities and Trustee Investment (Scotlandl Act 2005 and regulabons 6 and 8 of thè Charttiès Accounts (Scotlandl Regulations 20C6 las ameryledl. Basls for oplnlon We have been appointed audrtor under section 4411)(c) of the Charitses and Trustee Investment {Scotlandl Act 200S. section 151 01 the Charities Act 2011 and under the Companiès Act 20CE and report in accordancè with regulations made under those Acts. We conducted our audit in accordance wth Inlemational Standards on Audrting {UKI {ISAs IUKII and applicable law. Our responsibilities under those 51andard5 are fvrther described in the Audrtorfs responsibilities for the audrft of the financial statements section of our report. We are independent of the group and parent charitable company in accordance the ethical reqU1reff￿nts that are relevant to our audit of the financial statements in the UK, including the FRC'S Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the 8udrt evidence we have rt)taine(1 15 suffiGient and appropriate to provide a basis for our winK>n. Condusions relating to golng concem In auditing the financial stat￿entS. we have C1￿ClUde(j that the tru51ees' use of the wing concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have perfom)ed. we have not hjentified any material uncertainties relating lo events or conditions that. individually or colleCtNe￿, may cast Significant doubt on the group's or parent charitable company's ability to continue as a going concern for a period of at least hvefve mnths from when the financial slalements are authorised for issue. Our ￿Ponsibl11118$ and the resw)nsibilities of the Imste8S Wrth respect to going concern are described in the relevant sections of this ￿POrt. Oiher InfomiatSon The other information comprises the infomiatKJn induded in the Annual Report other than the financial st*ements and our audit￿$ report thereon. The trustees are responsib￿ for the other information contained wiihin the Annual Report. Our opinKJn on the financial ststements does rK)I cover the other information and, except to the extentotheFwse ex￿IcItty stated in our report. we do not express 8nyfom ofassurance conclusion thereon. Our responsibiltty is to read the other informatiort and. in doing so, consider vthelher the other information ts malerially inconsistent with the financial staternent5 or our krthvledge obtained in the course of the audit or otherwise appear5 to be materialty mi$5tate(l. If we identify such matèrial 1nconstster￿ieS or apparent material 24 Roy Castle Lung Cancw Foundation INDEPENDEFn AUDITOR'S REPORT TO THE TRUSTEES AND MEMBERS OF ROY CASTLE LUNG CANCER FOUNDATION missL*ments. we are required to detem11￿ whether this gives nse to a material misstatement In the financial staternents themselves. If. based on the work we have perfOrn￿d, we conclude that there is a material misstaternent of this ¢)ther information. we are required to report that fact. We have nothing to ￿port in this regard. Opinlons on other matter prescrlbed by the Companles Act 2006 In our opinion. based on the work undertaken In the course of the audit. the infomation given in the Di￿orS. Report prepared for the purFQ5es of company law and included within the Trustees. Annual Report for thè financial year for wh￿h the financial statements are prepared is consistent with the financk?I statements." and the Directors, Report, Include(J bmthin the Tnjstees. Annual Report has been prepared in accordance with applicable legal requiremenls Matter5 on which we are required tt> report by exception In the light of the kntrérf￿ge and understandiThJ of the group and the parent charitable company and thèir environment obtained in the course of the audrt. we have not ￿ent[ried material misststements in the Directors, Report. included wthin the Trustees. Annual Reporl. We have nothing to report in respect ofthe fo11c￿n9 matters where the Companies Act 20C6, the Charities Act 2011 and the Charit*s Accounts (Scotlandl Regulations 2fth las arrÈndedl requiré u8 lo report to you If, In our opinion.. SLrficient, adequate and properw)untsng recools have not been kept by the parent charitable company, or ￿tum$ adequate for ¢JJr audrt have not been received from branches not visited by us., or the parent charitable company financial statements a￿ not in agreement with the accounting records and retums.. or rkrtain disclosures of trustees, rwnUneratI￿ specrfied by law are not made; or we have not receiv￿1 all the Infornation and explanatKbns we requi￿ for our audrt. or the trustees We￿ not entit￿d to prepare the financial staternents in accordance with the small companies regime and take advantsge of the small companies exemptions in preparing the directors, report included within the trustees, annual report and from the requirements to prepare a strategic report. Responsibilities of trustees As explained more fully in the Statement of Trustees. Responsibilrties set out on page 22 the trustees (who are also the directors of the charitable cc¥npany for the purposes of cornpany 18wI are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and for such intemal control as the trustees delemine Is necessary to enable the preparation of financial statements that are free from material misstalement. whether due to fraud or error. In preparing the financial statements, Ihè trust*5 are responsible for a5sessirrfJ the group's and parent charitable company's ability to continue a5 3 going concem. d15closiThJ. as applicable, matters related to going concern and using the going concern basis of accounting unless the trust&s either intend to Iwuidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so. Auditorfs responsibilities for the audit of the financial statements Our objectives are to obtain reasonable assurance aboui whether Ihe finawal statemenis as a whole are free from mateftal misstatement, whether due to traud or error. and to issue an auditols report that Includes our opinion. Reasonable assurance is a h￿h ￿Ve1 of assurnnce. bLrt Is not a gLJarantee thal an audrt COnd￿ted in accofdance with ISAS IUKI will a￿ayS detect a material misstatement when It exists Misstatèments can arise from fraud or error and ale considered material rf. indiv¥Jually or in the aggregate. they could [eaS￿ablY be expected to influence the ec¢Jn¢yNic deu5ions of user5 taken on the basis of these financial statements 25 Roy Castle Lung Canctr Foundation INDEPENDENT AUDITOR'S REPORTTO THE TRUSTEES AND MEMBERS OF ROY CASTLE LUNG CANCER FOUNDATION Tho extent to which the audit wa5 ¢onsid•rod capable of dets¢tlng irregularities. including fraud Irregularities a￿ instances of non-complkance wrth laws and reguLations. The objectives of our audit are lo obtain sufficient appropriate audrt ey￿enCe regarding compliance wtlh laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements, lo perfL%Th audit procedures to help identify instances of non-wmplkAn¢e with other laws and regulations that may have a material effecl on the financial statemerrts, and to reswnd appropriatety to idenlffied or suspected non- mplHn¢e with laws an¢J regulat￿nS identtfied during th6 audit. In relation lo fraud, the objectives of our audit are lo identfy and assess the risk of material mis$t*emenl of the financial statements due to fraud, to obtain sufficient appropriate audit eviden￿ regarding the assessed ri5k5 of material misstatemeni due to fraud through de5uning and implementing appropriate re¥)onses and lo respond appropriately to fraud or suspected fraud identified during the audit. H¢wever, it is the primary responsibilty of management. wf(h the overs￿ht of those Gharged with govgrnance, lo ensure that the entity'¥ operations are corKluctèd in accordance with Ihe provisKJns of law5 and regulations and for the prevention and detection of fraud. In identifying and assessing risks of material misslatement in reS￿t of irregular￿.eS. including fraud. the group aud(( engagement team.. obtained an understanding of the nature of the sector. induding the legal and regulatory frameworks that the group and parent Charitab￿ company operate in and how the group and parent charitable company are comptying wrth the ￿saI and regulalw frameworks. inquired of management, and those charged with g0veman￿. aboLrt their own identrfication and assessment of the risks of itregularities. including any known xlual. suspected or alleged instances of fraud". discussed matters abcwjt non•complianGe wrth laws and wulations and how fraud might ¢xcur including a55essmenl of how and where the financial statements may be susceptible lo fraud. As a result of these pro¢odures we cons¥Jer the most sunificanl law5 and regulations Ihal have a direct impact on the financial statement5 are FRS 102, Charrties SORP {FRS 1021, thnpanies Act 2006, Charities Act 2011. Charities and Twslee Investment Iscotland) Act 2005 and Ihe parent charitable company's goveming document. We performed audit procedures to detect non-C(¥npliar￿s whieh may have a malerial impact on the financial statements which included rewwng the financial statements Including the Trustees. Report and remaining alert to new or unusual transactions which may not be in accordanee with the governing documents. The most significant laws and regulalions that have an indirect irnpael on the finan¢ial slalements are those in relation to employment law (including pensions). We perfomied audit procedures to inquire of management and those charged with governance whelher the gr￿p is in Compliance with these laws and regulations and inspected corre5pondenee with wulatory authorrties The group audit engagement team identtfied the risk of management overr￿Se of controls and incc*me from donations arKI legacies. charitable actmties, other trading and other income as the areas where the financial $tstements were most SL$S￿p11￿le to material misslatement due to fraud. Audit procedures performed inclucled but were not limited lo lesling manLJal joumal entries and other adjustments. evaluating the business rationale in relation to signifunt, unusual transactions arKJ tranS￿tionS entered Into outside the normal course of business, challengingjudgments and estirnates. Income testing included agreeing a sampk of individual Income Iran5actK)ns in the year back lo source documentation and bank receipt. ensuring ￿ognISed in the appropriate Category and fund, lesting cut off weeks either side of the year end to ensure a sample of transactions were recorded in the appropriate period, sample checking controls around trading (shops I rètail) reconciliations and 26 Roy Castle Lung Cancèr Foundation INDEPENDENT AUDITOR'S REPORT TO THE TrUSTEES AND MEMBERS OF ROY CA3TLE LUNG CANCER FOUNDATION system postings and an overall reCOr￿lI1*10n of cash receiv&Y in the bank to inoynè recognised for Ihe trading e￿Ment. A further descThption of our responsibililv&5 for the audit of the f1nanual statements is kncated on the Financial Reporting Council's website at http.'1l￿I.frc.0rg.UkJaudr(0fsreSpOnSIbl1itIe$. This description forms part of our audrtorfs report. Use of our rÈport This report is made èxclusivety to the members, as a body. in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable cornpanys trustees, a5 4 body, in aw)rdanGe with 3ect*?n 4411 Ilcl of the Chanties and Trustee Investrnent (Scotlandl Ad 2005 and regLJJaiion 1D of the Charrtie5 Accounts (Scotlandl Regulat￿n$ 20(fi las amended) and the Charities Act 2011. Our audit work has beèn undertaken so that wè mvJhl state to the mernbers and the charitable company's trust*s those matters we a￿ required to stsle to them in an audito¢s report and for no other purpose. To the fvllest exlent pernitted by law, we do Trot aGtspt or assume responsibilrty to anyone othei than the Chantab￿ company. Its mernbers as a body. and it$ trustees as a body. for our #udit worK for this report. or for the opinions we have fomed. Laura Inglesby FCA (SenK)r statutory audrtorl For and on behalf of RSM UK AUDIT LLP, StatuioryAudbtor Chartered Accounlants 14th Fh)or 20 Chapel Street Liverpool L3 9AG Date. 13/12/24 RSM UK AUD1T LLP 15 eligibte lo act as an audrtor in temis of section 1212 of the Companies Act 2006. 27 Roy Castle Lung Cancer Foundation Consolidat•d Stat￿￿nt of Flnancial Athiities (inthding Income and Exp￿dIt￿re A¢¢ountl for the y•ar ended 31 December 2023 Unrgstrl¢tgd Rostricted Funds Funds 2023 2023 Total Punds 2023 T¢)tal unds 2022 Income from: Donation5 & legacies Charitablè activities Othèr trading activitEs Investments Other 10 11 12 13 14 1.313.542 14,900 3.038.280 23,271 150 581.566 1.895,108 14.￿0 3.038.280 23,271 150 2,457.150 7,814 2,770.813 28.352 41.937 Total income 4.390.143 $81.566 4.971,709 5,306.066 Expenditurn on: Raising funds Charitable ￿tIVitIeS 15 16 3.505.2C6 1,335.143 27.986 767.881 3.533, 192 2.103,024 3,367.873 1,937,588 Total expenditure 4.840,349 795,867 5.636,216 5,305,459 Net gainlllossl on investments 27 20.056 20,056 180,9521 N•t expenditure (430.1501 1214.3011 1644.451} {80,3451 Net movemertl in funds 1430.1501 (214.301) {644.4511 180.3451 Reconciliation of funds:_ Totsl funds brought forward- as restated $07,641 745,532 1.253.173 1.333.518 Transfer between fLtnds 8.W3 (8.003) Total tunds carrled forward 85,494 523.228 608.722 1.253.173 All a¢tlvltl•$ derive frorn continuing operatlons. The notes on pagos 34 to 65 fomi an integral part of these financlal statements. 28 Roy Castte Lung Cancer Foundatlon Charity Onty Statèmènt of Financial Activitia lincluding Income and Expendrture Accourrt) fof the year •nd8d 31 December 2023 Unrestricted Restricted Funds Funds 2023 2023 Total Funds 2023 Total Funds 2022 Income from." Notès Donation$ & legaaos Charitable activities Othèr trading activities Investments Othèr 18 19 20 21 1.329.758 I4.￿)0 344,992 23.866 581.566 1.911.324 14.900 344.992 23,8S6 2.424.539 7.814 294,803 29,2S3 41.937 Total incom• 1,713,516 581,566 2.295.082 2,798.358 Expenditure on- Raising funds Charitable a¢tivilies 23 24 905.115 1.319.682 27,986 767.881 933,101 2.087.563 887.685 1.892.735 T¢tsi 0X￿ndftUr• 2,224.797 795.867 3.020.664 2.780.420 Net gainlllossl on investments 27 20,056 20.058 180,952) Net expenditure 1491.225) 1214.3011 (705.S261 163.016} Net movement in funds {491.2251 (214.3011 {705.5261 163.Q161 Rèconciliation of funds=. Total funds brought forward- as restat•d 645,191 705.326 1.350,517 1,413,533 Transfer be￿een funds 8.003 18,0031 Total funds carried forward 161.969 483.022 644.991 1,350.517 All gains and losses recognised in the year are included above. Thè notès on pagÈ$ 34 to 65 forrn an integral part of these financial statements. 29 Roy Castle Lung Caneor Foundatlon Company number: 03059425 Consolidatèd Balanu Sheel as at 31 Oecomber 2023 2023 2022 a5 rgstated Notes Flxed assets Tangible assets Investments 28 29 101.070 669.783 113.407 873.367 Total fixed assats 770.853 986,774 Current assets Stock5 Debtors Cash at bank and in hand 31 32 106.614 846,329 39,857 86.998 1.151,957 211.347 Total current assets 992.800 1.450.302 Creditors- amounts lalling due within one year 33 (￿3.176) {895,583} Net current assats 2S,624 554,719 Total assets less current liabilities 800.477 1.541,493 Creditots: amounts falling due after rnore than one year (73,333} (113.3331 (73.3331 1113,3331 Provlslons for Ilabllltl8S 1118,4221 1174,9871 The total net assets tsf tho group 608.722 1,253,173 The t¢)tsl net assets of the group are funded by the funds of the Charity, as follows- Restrlcted funds Restri¢led Revenue Funds 41 523.228 745,532 Unrestricted Funds Unrestri¢ted Revenue Funds 41 85,494 507,641 Total group funds 608.722 1.253,173 The a¢￿￿nIS have b¢en prepared in accordan￿ w>th the provisrons in Part 15 of the Companies Act 201 applicable to CC￿npaTrieS subject to the small companies regime. Approved and authonsed for issue by the l>)ard of trustees ¢)n 13 Oecember 2024 and signed on their beha by Euan Imn6 Euan Imrie Truslee The notes on pages 34 to 65 form an integral part of these ffinancial slalements. 30 Roy Gastle Lung Cancor Foundation Cornpany number: 03059425 Charlty Only Balanc• Short as at 31 0￿¢mber 2023 2023 2022 as restated Notes F5xed assets Tang1D￿ assets Investments 28 29 9,345 799,378 12.109 873,367 Total fixed assets BO8.723 885,476 Curront ass8ts Stocks Debtors due within one year Debtors due over one year Cash 8t bank and in hand 31 32 32 27.852 643.273 16.575 1,060,778 129,592 121,679 27.053 Total ¢ufTent assets 698.178 1.328.624 Creditors= amounts falllng due within one year 33 1763,7841 (733.31SI Net Cil Trent Iliabilitiesyassets 165,6(61 595.308 Total a55ets less current liabilities 743.117 1.480,784 Credi¢ors: amounts falling due after ffl0￿ than one y•ar (73.3331 1113,3331 173.3331 {113.3331 Provisions for liabllitsès 124,7931 116,9341 The total net assets of the charity 644.991 1.350,517 The total net assets of th8 charity are funded lyrf the funds of the charity. as follows:_ Restricted funds Restn¢ted Revenue Funds 41 483,022 705,326 Unrèstricted Fund Unresiricted R¢venue Funds 41 181.￿9 645.191 Total Charity funds 644.991 1.350.517 The aGcount5 have b￿n p￿Pared in accordance with the pn)ViSK)ns in Part 1 S of the Companies Aat 20r applicable to companies subject to the small compantes regime. Approved and authorised for issue by the board of trustees on 13 December 2024 and signed on their beha Euan Imrie Trustee The notes on pages 34 to 65 foim an integral part of these finanual statements. 31 Roy Castle Lung Cancer Foundation Consolidated Statement of Cash Flows for the year ended 31 December 2023 2023 2022 {as reststedl Cash flows from operating activities Not cash used in operating activities as shown below 1303,6571 190,7761 Cash flows from Investing activitles Interest received Dividends received Purchase of property, plant and equipment Receipts from sale of tsngible fixed assets Proceeds from sa￿S of investments Purchase of Investrrents Increase In cash hèkl for investment 826 22.445 127.596} 170 28,182 118,1081 782 127,410 (105,5511 66.375 202.772 133,504) 7.224 N•t cash provided by investing activitles 172.167 99.260 Cash flows from financing activities Repayments of boffowings 140,000) 140.0001 Net ¢ash used In financing activilies 140,CK)O) 140.000 Net deGrease in cash and ¢a$h equiya￿nts 37 1171.490) 131,5161 Cash and cash equivalent5 at the beginning of the year 211.347 242,863 Cash and cash equivalents at the end of the year 37 39,857 211,347 Reconciliation of net expenditure to netcash llow operatlng actfvbtles Net expenditure shcwn in the Statement of Financial Aclivilies 1644,451} {80.3451 Adjustments for:. Depreciation Charges Net Igainwoss on investment assets Dividends, interèst and rents frtyn inveslment Reali5ed gain on investments Increase in stocks DeC￿aSe1{1nCrÈas&I in deblors IncreasellDecreasel in credrtors (Deereaselnncwse in prowsKJns 39.935 (20.0561 123.2711 47,145 (19.6161 305.628 67,594 {56,5651 56.257 80,952 128,3S2) 49.343 113,067} {117,728) 156.6021 18,766 Ngt cash used in operating activities 1303.657) 190.7761 Analysis of cash and thish equivalents Cash at bank and in hand 39.857 211,347 Total cash and cash equlvalents 39.857 211.347 The slalement of cashll¢)ws has been restated due lo a ciassificalÈon error last year. The rea1ised gains on investments has been moved frcfft cash flws from invesbng a¢livrties to cash flows from operating activities. 32 Roy Castle Lung Cancèr Foundation Charity OFhly Ststwnent of Ca¥h FI￿3 for Ihe year end8d 31 L)ocwnber 2023 2023 2022 las rtstated} Cash flows usod in operating activilies Net cash usod in owriting activities as shrywn b•l*)w 1251,0421 175,1121 Cash flows from invesling activitie5 Interest received Dividends receNed Purchase of propety, plant and equipment Proceeds from sales of Investrnents Purchase of Inv8Stments Increase in cash heid for investsnent 1.421 22,445 {3.942 2J2.772 133.5041 7.224 1,082 28.182 15,3471 127,410 1105.5511 66,375 Net cash provided by Investing adi¥ttOes 196,416 112,151 Cash Ilows from Ilnanclng acuvllles Repayment of borrowings 140.0001 {40,OODI Net cash us•d in financing activitl 140,0001 14L),0001 Net decrease in cash and cash equivalents 37 194.6261 12,961} Cash and cash eqUiVa￿￿t￿ at the beginning of the year 121.679 124,644 Cash and ush equival•nts at the end of th• year 37 27,OSJ 121.679 Roconciliation of net expènditur• to net cash fkvwfrom oper￿Ing activities Net expenditu￿ shown in the Statement of Financial Actrvths 1705.526 163,0161 Adjustments for- Depreciation charges Net Igainlllo55 on inveslment assets Dividends. Interést and rents from investments Realised gain on investments Ilncreasel in stocks Increaselldecrea5el in debtor5 Decreasellincreasel In c1￿￿￿T5 Increase in provish)ns 6.707 {2LI.0561 123.8661 47.145 111,2771 417.505 30,467 7.859 17.601 80.952 129.2631 49.343 {4,1091 143.CX)41 185,0501 1,434 Net debt used by operating aGtivities 1251,0421 {75.1121 Analysis of cash and Cash equivalents Cash at bank and in hand 27.053 121,679 Total cash and cash equivalents 27.053 121,679 The statement OfCashfk￿ has been restated due to a classification error last year The realised gain5 on investrnents h85 beèn moved from cash fi(Avs fmm investing actIv(t￿$ to cash llows from t4)erating aGtivities. 33 Roy Castle Lung Cancer Foundation Not8S to the Consolidated Accounts for the year ended 31 De¢ember 2023 Accounting policies Poli¢i•s relating to the productlon olthe accoun Basts of preparation and a¢￿Unting cOnV￿tion These consolidated accounts have been p￿Pared on the a¢cruals basis. under the historical cost Convention except for listed investrnents which are slated al market value, and in accordance with Accounting and Rep)rting by Charities". Statement of Recommended Practice applicable to charities preparing their aGcounts in accordance wrth the Financial Reporting Standard applicable in the UK and Republ￿ of Ireland IFRS102) (effective 1 January 20191, the Companies Act 2006 and Charits"es A¢t 2011. Roy Castle Lung Cancer Foundation meèts the definrtK)n of a PLbblic benefil entity under FRS102. The registered offiee and prinupal place of business is Cotton Exchange. Old Hall Street, Liverpool, England, L3 9LQ. The Statement of FinancTral Acliwt* ISOFA) and balance sheet cwsolKlate the financial slalements ofthe Charity and its subsidiary undertakings. The resutts. assets and liabilities of the subsidiaries are consolidated on a line by line basis The accounts are prepared in steding, which is the funct*?nal currency of the charity. Monetary amounts in these financial slaternents are rounded lo the nearest £ Control of members of the group The parent charity has concluded that control exists over rts subsKlkgries for the following reasons: _ They are either a wholty owned subsidiary wilh directors appoinled by the Roy Castle Lung Cancer Foundation or a charity and cornpany limrted by guaranlee and controlled by tru51ees appointcd by the Roy Castle Lung r.#nrA3.r Foundation_ L•gal Status Roy Castle Lung Cancer Foundation (the Chari￿1 is a company lirniled by guarantee {Companies House No. 030594251 and a registered charity (Registered Chanty No 1046854 {England and Wales), SC037596 {Scollandl and 006171 F {Isle of Manl). It is govemed by Memorandum and Articles of ASs￿latIon dated 31 JanLJary 2011. The liability of each member in the event of winding up 15 £10. Thè company is reglstered as a charity with both the Chanty C(*nm1ss￿n and the Office of the Scottish Charity Regulator. Goln9 Concem Over the period since Covid19 the charrty has taken prudent actions to prolect rts&lf and minimise the negative impact of the subsequenl econom￿ downtum ty reducing costs, looking for alternative Soul￿s of lunding and taking advantage of whatever govemment aKI has been made available. Many of the m￿lIcat and ￿Search staff working on our vital lung cancer ￿searCh were walled onto the medical front line during Cowd19 ar￿ over the last 2 years $0 sadw the research ￿mmunitY has still to fully recover wrth the resutt that there has been ￿sS demand for research funding. The charity has therefore made a conscious decision to diversfy the types of research it will fulld lo increase futu￿ resear¢h activity and spend. The Charity applied for and receNed in October 2020 a CBIL loan back￿ by thè Government, the balance of this outstsnding at the yearend was £73.33312022_ £153.333). Roy Castle Lung Cancer Foun(lation Notes to the Cansolidat•d Atrounts for thè year end•d 31 Dec•mb•r 2023 A¢¢ounting policies I￿ntInued) As a result of the above poirtrts, and 85 a resutt of the cost cuts implemenby, the latest forecast for 2024 indicates a surplus of £1 Iok. Sadly. these cvts have i￿luded a reduction in roles, mainly through positions not bw.ng recruited to butthère have also been several redundanc*s. Further steps will be taken thft)ughout 2025 to furthèr reduce costs and generate new inwme streams that the Gurrent forecast surplus can b8 improved upTri. Forecasts have prepared to cover until December 2rJ25 show an improving POSltion year on year. The charity has had a strong long iern investment policy for many years, tra￿rt￿naIty hO￿ing nearly £1m of fixed assets of wh￿￿ over £800k a￿ in reality COFwertibie investn*nts that can be liqu￿ated at short notice without Signif￿nI ri5kof crystali51ng k>sses. The level of cash and investments has dropped lolltyuing the l()sses in 2023to £70(X. Howe¥ef.thhs iss1￿ p&￿￿ed as a5ecuTefwndation for Ihechantyto opera fr¢xn. During 2024. the level of cash and re5eryes has both risen and fallen again as the chaiity receNed some significant outslanding legacies. nevefthele55. cufTenVy over £71YJk in outstanding legxies hs due to Ihtr charrty and thus the current cash and investment baLance stsnds at £450k in October 2024. Within the reserves, the level of unrestricted reserves stands * £85k 12022" £508k as restated) and restricted resèrves are £523k12022". £746k a5 resiatedl. Wni151 the significance of the balance olfund5 held a5 restricted Is re¢ognised as a concern, the fact that as rnuch of the ch3rity's obligations in respect of research. patient SUPFMxi. GLCC prc4e¢ts and olheT charitable actyvrties. all of which form part of the core of the charrty's actiwties and thus costs, are wrthin the remil of much ofthese restri￿￿ funds mrtKJates the risk The Trustees have therelore concluded that charrty ￿ griNJp have sufficEnl fLJnds to be sble 10 coniinue in existence for the foreseeable future and Ihus o)nbnue to adopt the g￿n9 concem basis of accounting in prepanng the financial statements. Policies relating to catègoriès of income and income ￿09nttIOn. al A¢couniln9 for def•rred income and Income received in advancg Vvhere terms and conditions relating to incorre have not been met or uncertainty exists as to whether the charrty can meet any terms or cOndrt￿ns otherwise within rts rthtrol, income is not recognised bLrt IS deferred as a liability until tt is prcbable that the terms c¥ conditions impose(I can be met. Any grant that is subiectto perfomance-related condrtv)ns received in advance of delivering the goods and services requir8d by that condition or is subject to Un￿￿1 conditions wholty outside the control of the recipient charty, is accounted for as a liabilty a￿1 shown on the baLance sheet as deferred income. Oeferred tncome is released to inc￿rne in the reporting peiiod in the perfomance-related or other COndrt￿Jrt$ that limit reCOgnrt￿ft are met. Vvhen income frryr a grant or donatron has rk)t been recognised due to the conditions applying to the gift not being wholty within the control of the recipient charity. it i8 disckjsed as a contingent asset rf receipt of the grant or dtsnation is probable once those condrtions are mel. Where time related ¢onditvns are imposed or implied by a funder. then the income Is apportioned to the time ￿n0￿$ concerned and, whefe applicab￿. is accounted for a5 a liability and shtyrfn on the balance sheet as deferred Income. When granis are recewed In advance ol the expen￿rtU￿ on the actNity fun¢Jed by them, but there are no specfft time rdated conditions, then the incoffe is not deferred. Any condition that allows for the recovery by Ihe donor of any unexpended part of a grant ￿￿$ not prevent rec¢gnition of the inccme corKeined. but a liabilty to any repaymenl is reC￿gniSed when repayment b&com￿ probable. 35 Roy Castle Lung Cancer Foundation Notes to the Consolidat•d Accounts for the year ended 31 DeCem￿r 2023 Accounting policies Icontinuedl bl Inc¢m• from legacles Ir￿c￿ne from legacies is re¢c*Jnised when the charity has surfic￿t evidence that a gift has been left to them, that where required. probate has been granted, the executor is sattsfied that the propety in question will not be required to satisfy claims in the estate, that rt is probable that the amount will be received by the charity. and the amount to be received can be estirnated wrth sufficient acLuraGy, and Ih8t any condrtions attached to the legaGy are either within thè control of thè chatty have been mèt. Where a payrnent is received from an estste ￿ is notffied as receivable by the exeeutors after the reporting dale and before the accounts are authorised for issue bul It is clear that the payment had been agreed by the executors prior to the end of the reporting period. then the amount Con￿rned is treated as an adjusting event and accrued as income in the accounting pentsJ rf reeeipt is probable. Where the charity has established en1itkn￿I to a ￿acY but Ihere is uneertainty as to the amount of the payment. details of the legacy are ¢Ji5ck)5ed as a conliTrgenl asset until the criteria for income recognition are mèt. Where a legacy is subJ"￿t lo the Interest of a lrfe tenant. the legacy is not recognised as income until the death of the life tenant lthere there is any doubt that fvll settlement of a legacy debtor will be received, then an adjustment is made to reduce the arn￿jnt of the *acy debtor and ￿gacY inc￿ne rather than charging the adjustment as expenditure In the Statement of Financial Actith. cl Donated goods. facilities and ser¥l¢es Donated fixed assets are recognised at the current fairvalue. All such donats.ons are recogni5ed a5 donation Income and debited lo fued assets. Donated goods that are not fixed assets are ￿0VAted for at a fair value unless rf( is impractul to reliably measure the value of the donated rtems. It is deerned impr￿l￿able to measijre the fair value of tjonaled for resale and that costs of valuation oulweigh the benefrts, as a Consequen￿ the value ol donated goods are recognised as income when sold. Donated servkrE5 and faGilities (including seconded staff and use of propetyl are in¢luded in the a￿unt$ on the basis of the value ￿ the grft to the charity. All donated services and facilities are recognised as donation income when received (provided the value of the gift can be measured reliably) and recognised as an expense wrth an equivalent value Policies relating to expenditure on goods and services provided to the charity. al Recognttlon of liabilities and ex￿ndIture A liabilty, and the related expendrture. is recognised v4hen a legal or con$lructNe obligation exists as a resuK of a past event. and when it is more likety than not Ihat a transferof economic ber¢efits will be required in settlement, and when the amount of the obl￿atIon Can be measured or ￿liablY eslimaled. Lwbilities arising from futu￿ funding commitments and con$tructNe obligations, including perfomance related grants, where the timing or the amount of the fvlure expendrture required lo settle the obligation are uncertain, give rise to a provision in the accourrts. wh￿h is revi￿￿ed at the accounting year end. The provision is increased to rellect any Increases in liabilrties and is decreased by the ulilisation of any provision wrthin the period reversed rf any provisK)n is no k)nger required. These movements are charged or credited to thè respeciive fvnds and actwfcies to which the provision relates. Roy Castle Lung Canc•T Foundation Not•5 to the Consolidated Accounts for the y•aT ended 31 D•cembor 2023 Aceountlng policl8s (continued) bl Allocating costs to adivities Direet costs that are specrficalty rekted to an activty are albcated to that actNity. Shared direct costs and support costs are apportioned betr￿en activities. The basis for apportionment. which is ¢onsi*¢nlty applied. and proporth)natè to the arcumstances, is."- Direct stsff costs - Directty 811¢xated on the basts of b.me spent in connedion with any particular activity. Indlrectstafflng- on a pef cath basis, based ￿ the numberofpeople wployed within any particular activity. Indirect staff costs are albcaled as foll¢)￿." Direct￿$ and CEO. estsmaled timè spent on operatKJnal activities Finance. estimated b.me spent on governance and rwnaining costs alk)cated on numbèr of fvll-tirne equivalent IFTEI Staff HR. allocated on number of lull4ime equrvalent IFTEI staff excluding ￿searCh staff Office services and IT, althted on number of fu114ime equivalent IFTEI staff Premises relatèd costs - on a per caprta basi5. based on the number of people employed within any partKular activity. Non-specific support costs- on a per capita basis, based on the numbèr of people employed within any particular actrvity. Estimation t8chniqu85 used in apportioning o)sts are based on FTE time spent on activities. cl Vdunteers In acwrdance with the SORP. and in recognitK)n of the difficullies Jn placing a monetary value on the contribution from volunteers. the contribution of volunteer5 is included wrthin the income or expenditure of the chanty However. the trustees value the svJnrfrant contribution maje to Ihe activrties of the charty by unpaid volunteers and this is descrttjed rrnfe fulty in Note 7 and the front el￿ of the account5 Policies relating to assets. liabilityes and provisions and other matters. a) FIX￿ A￿et Invèstmtrnts Fixed asset investments in quoted shares, traded bonds. invesknent pr(wties and similar investments are shown initially al cost upon ￿qUiSIti.0ft and at iheir fair value through profrt and 1955. Fixed asset investments in unlisted eq￿rt￿ a￿ sh fundraising and £2,226,848 12022". £2,165,754) Sa￿ of donated arKI related gry)ds. All of the 2022 income was unrestricted. Roy Castle Lung Caneer Foundation Notss to the Congolidated Accounts for th• yDar ended 31 December 2023 13 Investrnent income - Consolidat•d UnrnstTbCt•d R•strict￿ Total Funds Funds Funds 2023 2023 2023 Totsl Funds 2022 0￿￿end IncoFne Bank Inte￿$t Receivable 22.445 826 28.182 170 826 23.271 23.271 28,352 All of 2022 incc¥ne was unrestricted. 14 Other- Corffjolidated Unrestricled Restrioted Total Funds Funds Funds 2023 2023 2023 Total Funds 2022 colon￿lfU$ grant income other inco￿￿ 22S 41,712 150 150 150 41.937 Of Ihe 2022 income. £41,531 was unrestrict￿￿ and £406 was restr￿ted. Othergovernment grants of £nil12022". £2251 relaiing to the Inte￿$t free benefft ineurred on a Coronavinjs Business Interruption Loan We￿ received by the Group in the year. 15 Expenditur• on raising funds and costs of investrnent management- Consolidated Unrestricted RestrKted Total Funds Funds Funds 2023 2023 2023 Total Funds 2022 Cost of fundraising activrties Marketing & advertising of fundraising Costs of seeking dOnat￿n$. grants and legacies Cost of operating social lotteries Costs ol staging fundraisFng events Costs of charity shop selling goods Gross wages and salaries - fundrajsing activitEs Other Direct Costs- fundraising actNities Staff Training & Welfare- fundraising activitie5 Travel and Sub515tence- fundraising aciivilEs 121.927 41.764 269 2.091 105.189 2.453.227 569.512 205.940 40 5,247 15.80Q 4.807 137.727 89,417 46.571 73.461 269 556 2.091 2.135 105.189 65,748 2,453.227 2,345,095 569.632 503.363 213,199 282,520 40 289 5.247 5.289 120 7.259 3.505.206 27.986 3.533.192 3.367.873 Of the 2D22 expenditure, £3,360,830 was unrestricted arxj £7.043 restrTGted. 45 Roy Castle Lung Cancer Foundatlon Notes to the Consolidatsd Accounts for th• yèar ended 31 DècembÈr 2023 16 Expenditure on charitable activities - Consolidated Stsff Costs 2023 Total Funds 2023 Totsl Funds 2022 Other 2023 Note Direct spending Restricted Unrestricted 213.925 133.584 420,070 148,436 633.995 250,946 282,020 487,840 347.509 568.SCE 916.015 738.786 Grant fundlng Organisa150n grants Staff costs 26 12.946 12.948 42.254 139,984 38,451 42,254 42.254 12,946 55.200 178,435 Supportcosts Staff costs Pfemises costs Legal and professional costs Financial Olher 788,104 788.104 97.317 107.339 12.465 41.848 510,784 66,503 15,294 56.447 305,895 97.317 107.339 12.465 41.848 788.104 258.969 1.047.073 954.923 Governance costs Audit fees Accountancy fees Taxatson 37.750 28.711 18.275 37,750 28,711 18,275 35,100 30.342 1.177.867 925,157 2,103,024 1,937,586 Of Ihe £2.103,024 {2022.' £1,937.5861 expenditure. £767.881 {2022.' £348.2881 related to restricted fund$ and £1,335,14312022'. £1,589,298) related to unrestricted funds. 17 Summary of charltable costs by activity _ Consolidated Grant Support funding Govemance ¢)sts of activities Direct Costs Total 2023 Total 2022 Research Support Preven 916.015 437.867 247,4 361.716 55.2 27,792 1,436,874 1.196,722 1 5,709 263.199 419,637 41.235 402,951 321.227 916.015 1.047.073 55,200 84,736 2.103.024 1,937.586 46 Roy Castle Lung Cancer Foundation Notes to th• Consolidatod Accounts for the year ènded 31 (lecembèr 2023 18 Donatlons and L•gacl•s- Charity only un￿tricted Restricted Funds Funds 2023 2023 Total Funds 2023 Total Funds 2022 tk>nation$ and gifts frorn individuals Individual Giving Payroll Givin9 341.426 69.%5 341,426 69,965 304,204 78,429 411.391 411.391 382,633 Lega¢ies rneeivabla Leg￿leS receivable 351.369 351,3S9 902,102 351.369 351.369 902.102 Revenue grants and donations from non*ubli¢ Ix>dies co￿orate Grants Trusts 73.650 25.850 73.650 113.OTrJ 67,317 146,359 87.150 99.500 87.150 186.650 213,876 Sponsorship Pause for Hope Sponsorships 1.715 492.701 1.715 503.539 1,S56 487.511 10.838 10.838 494.416 50S.254 489.067 In Mtmoriam In Memonam 179.059 179.059 228,137 179,059 179.059 228.137 Glft Aid on Ckjnations Gift Aid on Donations Gift aid from SLJbsiduary 135.732 141.869 135,732 141,869 86.638 122,286 277,601 277,601 208.924 Total Donation$ and Legacley- Charity 1.329.758 581.566 1.911,324 2,424.539 Of the 2022 Income, £1.￿0,670 was unrestricted and £523.869 was restrtcted. 47 Roy Castle Lung Cancer Foundatlon Notes to the Consolidated A¢¢ounts for the y&ar eTrded 31 December 2023 19 Incorne frorn charitable activities- Charity onty Unrestrictod Restricted Funds Funds 2023 2023 Total Funds 2023 Total Funds 2022 Charitable income from lunde Communty engagement 14.900 14,9 7,814 Total Income from charitable a¢ti¥ilEes 14.900 14,900 7,814 Total income from charItab￿ activrties all related to preventk)n. Of the 2022 income. £nil was unresth.cted and £7,814 was resth"cted. 20 In¢orne from other trnding activities - Charlty onty Unrestrlcted R8StrSct8d Total Funds Funds Funds 2023 2023 2023 Total Funds 2022 Income from fundraising events Other in¢ome 330.318 14,674 330,318 14,674 283.589 11,214 344.992 344.992 294.803 Totsl incorne from othei trading activibes split by activity all related lo fundraising activiiies. All of the 2022 incorne was unrestricted. 21 Investment income- Charity Only Unrestricted Restricted Total Funds Funds Funds 2023 2023 2023 Total Funds 2022 Dividend Income Bank Inte￿st Receivab 22.445 1.421 22,445 1,421 28.182 1,081 23.866 23.866 29.263 All of 2022 incom8 was unrestricted. 48 Roy Castle Lung Cancer Foundatlon Notes tts the Consolidated A¢¢ounts for th¢ year •nded 31 Dec•mber 2023 her- Charty Unrestricted Rèstricted Total Funds Funds Funds 2023 2023 2023 Tot81 Funds 2022 Coronavirus grant income Other incomè 225 41,712 41.937 Of the £41,937 of 2022 inccme. £41.531 was unrestricled and £4￿ was rest￿ted. Oihergovemment grants of£nil {2022. Q25} relab.ng to the rntere5t free benefit i￿Urred on a Coronaviru$ Business Interruplion Loan were recewed by the chanly in the year 23 Expenditure on rais5ng funds and cctsts af investment management. Charity only Unrestrict•d Restrict•d Totsl Funds Funds Funds 2023 2023 2023 Total Funds 2022 Cost of fijndraising activities Marketing & advertising of fundraising Costs of seeking dOnat￿n$, grants and legacies Cost of operating social kjtteries Costs of stagin9 fundraising events Gross wages and salarEs- fundraising ￿t￿lIES Other Direct Costs- FLJndraising activities Staff Training & Welfare- Fundraising aciivrties Travel and Substslence- FundraisiTrg actNitEs 71,319 41.764 269 2.091 8Q.813 569.512 134.061 15,800 4,807 87,119 46.571 269 2,091 80.813 $89,632 141.320 40 S.246 29,417 33.461 556 2,135 45.748 694,985 77,427 289 3,667 120 7.259 5.246 90S.11S 27,986 933.101 887.685 the £887.685 of 2022 expenditu￿. £880.642 was unrestncted and £7.043 wa5 restricted. 49 Roy Castle Lung Cancer Foundation Notes to the Consolidated Accounts for the yur ended 31 Decwnber 2023 24 Expenditure on charitable activities - Charity Staff Total Funds 2023 Total Funds 2022 Other 2023 Nole 2023 Direct Spending Restricted Unrestricted 213.925 133,584 420.070 633,995 250.946 147.435 281,019 487,840 347.509 567.505 915,014 738,786 Grant fundlng Organisation grants Stsff Costs 26 12.946 12,946 42,254 139.984 38.451 42.254 42.254 12,946 55,200 178,435 Support costs Staff cosls Prem15e5 costs Legal and professional costs Deprecialionlintere5t Other- admin 788,104 788.104 97.317 107.339 57.421 6.71 510,784 66.497 15,294 17.601 305.896 97.317 107,339 57,421 6,706 788.104 268.783 1.056.887 916.072 Governance Costs: Audit fees Acccmjntancy fees 37,750 22,712 37.750 22.712 35,100 24,342 1,177,867 909.696 2.087,563 1.892,735 Of the £2,087,56312022.' £1.892,735) expenditure £761.881 {2022". £348.2881 related to restricted fund5 and was ¢ategoris8d as other expenditure. £1.319.68212022". £1,544.4471 related to unrestricted funds. 25 Summary of charitable costs by activity- Charity only Grant funding Governance of activities Direct Costs Support Total 2023 Total 2022 Research Support Prevention 915,014 441.971 249,810 365.106 55.200 25.284 1,437,469 1,175,336 14.291 264.101 407,607 20.887 385,993 309,792 915,014 1,056.887 60,462 2,087.563 1,892,735 so Roy Castle Lung Cancer Foundation Not•5 to th• Consolldated Accounts for the ye•r end•d 31 Deumber 2023 26 Breakdown of Grnnts to oryanisations Unrnstricted Restricted Total Funds Funds Funds 2023 2023 2023 Total Funds 2022 Unwersity of LNe￿O01 Oxford Brooks Univers Univefsity College London Community Engagement Research Programme University of Nottingharn University of Leeds University of Sheffield Universty of Manchester 9.532 73,511 9,532 73,511 (26.723) 16.2491 170,0791 166.496 1181 110.0001 119.1781 35.638 170.0791 {18) 12.946 12.946 139,984 The cre(Itt figures included above relate to grants pre￿0￿5￿ accrued which have been released in the year. 27 Investmènt galnslllosses) Unr•stricted Restrkt4d Total Funds Funds Funds 2023 2023 2023 Total Funds 2022 Groupand Charlty Listed Investments- Realised gains Listed investsrenls- Unrealised losses 47.14S 127,0891 47,145 49.34S 127,0891 1130.2971 Totsl realis•d and unrealised gainslllossesl 20,056 20,056 180,9521 All thè gainslllossesl on investments in 2022 wtse unrestrrted. 28 Tangible fixed assèts Res•arch office and computer equipment Leasehold land and buildinys Fixtur and fthings Group Group lotal Cost At 1 January 2023 Add((ions 519.844 9,154 359.560 18.442 481.170 1,360.574 27,596 At 31 Decembgr 2023 528,998 378.002 481,170 1,388.170 DeP￿latIon At 1 January 2023 Charge for tbe year 500,639 7.094 281.794 24,325 464.734 8.516 1,247.167 39,935 At 31 Decembèr 2023 507.733 306,119 473.250 1.287.102 Net l)ook valuè At 31 December 2023 21,267 71,883 7,920 101,070 At 31 December 2022 19,205 77,766 16.436 113,407 51 Roy Castle Lung Cancer Foundation Notes to the Con$olidated Accounts for the year ended 31 December 2023 28 Tangible fixed assets {coDtinuedl Resèarch office and computer equipment Leasehold land and buildings F[X￿r¢S and fitting5 Charfty Only Total Cost At 1 January 2023 Additions 6.783 46.039 3.943 350.685 403.507 3,942 At 310e¢omber 2023 6.783 49.982 350,685 407.449 Depreciation At 1 January 2023 Charge for the year 5.879 658 44,51 341,019 5.463 391,398 6,707 At 31 DeCern￿r 2023 6.537 45.086 346.482 398,105 N•t book value At 31 De￿mber 2023 248 4.8 4.203 9,345 At 31 December 2022 904 1,539 9,666 12,109 29 Investments held as fixed assets by tha Charity Investments Loans to In subsidiary subsidiary undertakings undertakings Other investments Total Carrying Value of investments Al 1 January 2023 Additions Cash movement Disposals Revaluation Reallocation 873,364 873.367 33.504 33,504 17,2241 17,2241 (202,7721 1202,7721 127,0891 127,0891 129,592_ 129.592 At 31 D•c•mb•r 2023 69.783 799,378 During the year, £129,592 was ￿alIC¢￿e￿ from lor)g tem) debtors to investments lo better reffect substance in that. whilst il is a long term kjan. rt 15 better rellectèd as fixed asset investment in a subsidiary, as the intention is that the balance will not be realised through nom￿1 trading operalion$ in th8 near future. The loan is due to be paid on 31 De￿rnber 2099 or ead*r rf m￿￿allY agreed. Interest is payable at the Bank of England base ralo. tt 1$ not ￿nsidered material to restate the compar3lives. The Other investments above are hekl by both the Charity and the Group. Group inve5tment5 are therefore £669,783 {£873,3641. Anatysis of other investments: 2023 2022 Cash Listed investments 17.483 652.300 24,716 848.648 669.783 873.364 52 Roy Castle Lung cancer Foundatlon Notes to the Consolldated Accounts for the year onded 31 0￿mb¢r 2023 29 Investments held as fixed assets by the Charity {continued) The company ho¢ds 20% or mre of the share capital of the folkywing ¢ompanies" Company Address Shares held DirKt Class Gut Films Limiled Roy Castle Retail Limited Roy Castle Trading Limrted Ordinary Ordinary Oréinary 100 100 100 1. Registered office address". Cotton Exchanp, Old Hall Street. LNetpwl. England. L3 9LQ 30 Subsidiary companiès Three tradlng Subsldlarles Roy Castle Retail Limrfted- Company number. 03604677 Roy cast￿ Trading Limit￿ - Company number. 03909935 Cut Films Limited- Company number 07313137 Prineiplè Activitiès Retail Charty Shtsp$ Charty and charitab￿ Events Provtsion of Charity Youth Projects Vvhere liability is limrted by shareholding. the an￿U￿t of the holding company's investment in each subsidiary 15 £1. which represents 100% of the 15sued ordinary share capital of each subsidiary. In all cases, the subsidiary is controlled by the holding company by wrtue of thè power to appoint directors to the board of the sUbS￿￿ry. All c¢ynpanies are incorporated in England and Wales and are exempt from audrt. The subsidiaries activrtie5 relate to tht)se of Ihe hokling company in that the subsidiaries are trading enterpns8s enga9ln9 in tiades sirnilar to the charrtable activilEs of Ihe holding company which donates its entire taxable trading profrt to the ho￿1￿￿ company by way of gift aid. Under Section 479A of the CompanEs Act 20(6, exemption frc¥n an audrt of the financial statemènts for the financial peric¥Y ending 31 December 2023 has been laken by the fOlk￿ing sUbS￿j1ary Compan￿.. Roy Castle Retail Limited1036f146771 Roy Castle Trading Limited {03909935) Cut Films Limited lQ731313n As required, the company guarantee5 al outstanding liabilitEs lo which the Subsidiary companie5. listed above, are subject to al the end of the financial period. until they are satisfied in full and the guarar¢tee is enforceable againsl the parent undertaking by any person to wh¢Jn the subsLdiary companies lisled above is liable in respect of those Ikabilities. 53 Roy Castle Lung Cancer Foundation Note5 to th• Consolidated A￿OuntS for the year ended 31 December 2023 30 Subsidiary ¢ompanies (Conlinued) A summary ol the financial statements ol the sutsidiaries Is:. Group Roy Castle Trading £'ooo Roy Castle Retail Cut Filrr Limited 2023 Total £'ooo £'ooo Assets and lunds Aggregate amount of assets Aggregate amount of liabilrfcies 88.447 (26,717) 398.410 (484.9481 3,480 1294,5831 490,337 18C6,2481 Aggregate amDunt of funds Profit ènd loss Tumover Expenses 61.730 186,5381 291.103 315,911 354.226 2,404,763 {212.358) 12.368,4D9) 2,758,989 (1,1911 12,581,958> Netprofit for the year before tax Interest paid Interest received Other operating income Gift aid payments rnade lo holding company Taxation 141M68 36.354 {1,0881 316 44.956 (1,1911 177.031 11,0881 316 44.956 {141,8681 118,2751 1141.868) (18,2751 NetprofiV(Ioss) lor the yearafter and gift aid 62.263 {1,191} 61,072 2023 2022 Restricted funds retained within charitable subsidiaries 40.208 40,208 31 Stock Group Charkty Only 2023 2022 2023 2022 Stctks 1(E.614 27,852 16.575 106.614 86.998 27.852 16.575 Costs of stock included in the statement of ffinanoal *ivrties amounted to £159.177 {2022.' £152.220). Stock includes an impairnt provision of £6,00012022.' £5.4471. Roy Castle Lung Cancer Foundation Notes to the Consolidated Accounts for the year ended 31 December 2023 31 Stock {Contlnued) Analysis olthè valuè of stt)ck by aed¥lty Group Charrty Only 2023 2022 2023 2022 Actlvlty Fundraising activities 27,852 Stocks for Sates of purchased and re￿ed GrK#ls 78.762 16,575 70,423 27.852 16,575 106.614 86,998 27.852 16.575 32 Debtors Group Charity Only 2023 2022 2023 2022 Amounts falling due wlthln one year. Trade debtors Amounts owed by group undertakings Prepayments and accrued incc*ne Other debtors 85.102 109,494 36,285 43,784 145.321 839,709 31,964 746,807 14.420 961,899 80,564 592.636 14.352 846.329 1,151.9S7 643.273 1.060.778 A provision for bad debts of £nil12022.' £4,834) wa5 incllthd against trade debtors. The arnounts owed by group undertakings are interest free and repayable on demand. Group ¢h•rity Only 2023 2022 2023 2022 Amounts falling du• aft•r morn than on• year. Intercornpany loan deblor 129.592 129,592 Total debtors 846.328 1.151.9S7 473.744 1.190.370 During the ear, £129.592 w35 realkKated frc)m long term deblor5 to Investments to better reflect substan in that, whi st it is a long tem) ban. rt is better reflected as fixed asset investment in a subsidiary, a5 the intention is thai the balance will n¢X be realised through nornial trading operations in the near future. The loan is due to be paid on 31 December 2099 or earfvr rf rnutually agreed Interest is payable al the Bank ol England base rate. It is not consi¢Jered material to reslate the comparatNes. 55 Roy Caslle Lung Cancer Foundation Notes to the Consolidated Accounts for the year ended 31 December 2023 33 Creditors: amounts falling due wlthin one year Group Charity Only 2022 Note 2023 2022 Trade ¢￿￿rtorS Amounts owed to group undertakings Accruals and deferred income PAYE. NIC VAT and other taxes Bank loan Corporation tax credrtor Othef creditors 477.390 140.410 68,704 27,660 173,825 64.154 40,OtsJ 35 240.284 64.154 40.IXJO 19.901 121.447 351.130 62.046 40,OCH) 260,576 62,046 40,000 301,997 139,950 301,990 963.176 895,583 763,7B4 733,316 There is a debenture in ￿ace dated 13 September 2020 in Roy Castle Retail Limited over leasehold property ol the company by Barclays Bank pk. The￿ is a cross guarantee befv￿en Roy Castle Retail Limited and Roy Castle Lung Foundathjn that relates lo a loan of £129A included within r￿te 29. The amount of bank loans repayab￿ induded in creditors due wilhin one year relates to a Coronavirus Bu$iness Interruption Loan receNed in 2020. The amounts owed to group undertakings are interest free and repayable on demand. 34 Creditors- amounts falling due after more than one year GTOUP Charity Only 2023 2022 2023 2022 Bank loan 73,333 113,333 73,333 113,333 73.333 113,333 73.333 113.333 The amount of bank k)ans repayable inclu¢Jed in ¢￿itorS after m￿e than one year relates to a Coronavirus Business Interruption Loan re￿[Ved in 2020. Inte￿st is charged at 2.9Wh over Bank of England base rate arKI the loan 15 5ecuied wilh a fixed and floating debèntuie over all assets of the Charity. The amount 15 repaid in rnonthty instalments with a final repayment date of October 2026. The amunt due after five years is £nil12022.' £nill. Deferred in¢om¢ Group Charity Only 2022 2023 2022 2023 Brought Forward Deferred in the year Amounts released In thè year 94,886 94.152 (94.8861 88,299 94.886 188.2991 94.886 88.267 {94,8861 88,299 94.886 188,2991 94,152 94,886 88,267 94,886 Deferred income of £5,885 {2022.' £8,O¢XI) relates to incorre received for the Charty's community engagernent project. £88.267 12022." £86.886} of the income deferred in the year relates to income for GLCC. 56 Roy caS￿e Lung Cancer Foundation Notes lo tho ftins0lld•t￿ Accounts for thè yèar ended 31 December 2023 36 Provisions for liablliti•s Group Charity Only 2023 2022 2023 2022 Dilapidats"on's provision Oeferred tax liobilrties 108.992 9.430 163.931 11,056 24.793 16,934 118.422 174.987 24.793 16,934 The deferred tax Iiabilty above relates to short tem timing differences and is expected to reverse within Ihe foreseeable future. move￿ent on pro￿s1onS artd deferr&Y ta tlilapidations provision Group Charity Only 2023 2022 2023 2022 At 1 January 202 Additional piovisions in ihe year (Releasedllutilised pmmsion 163.931 144.181 19.750 16,934 15,500 1,434 {54.9391 7.859 108,992 163,931 24,793 16.934 Deferred tsx Group Charlty Only 2023 2022 2023 2022 At 1 January 2023 Credit in the year 11,056 {1,6261 12.040 {9841 9,430 11.056 Dilapidation's provision The group and chanty hjve a present oblwjation to make g(¥Jd ￿aSehOld properties it occupies at the end of each respective property lease. Therefore, a dil3pidab.on prO￿510n is required based upon the expected discounted cost to make good the prcyerties £SSk of the provision was released in 202312022.. £nill with an addith)nal provision of £nil madeas at 31 Ckcember 202312022.. £20kl due to a review of likely property and lease termination dates. £109k provision Ir￿1￿¢JeS £25k In ￿latK)n to head office and £84k in relation to the shc4)s held by retail. 57 Roy &istle Lung CanGer Foundation Notes to the Consolidated A¢¢ounts for th¢ year ended 31 December 2023 37 Analysls of changes in net fundslldebt Group 0110112023 Cash IIow5 Non 180.9521 507.641 Charty Restricted Funds Sundry RCF Restricted ReseNes GLCC B￿hr1nger Ingleheirn Awareness Project Subsidiary Restricted Funds Cul Film5 Restricted Reserves 333.589 171,529 1109,6561 290.548 360,560 1340.7001 15461 395.462 310,408 1546} 40.208 40,208 Total restrfcted funds 663.799 532.089 {450,356) 745.532 Tolal Group Funds 1,333,518 5.306,066 15.305.459) {80.952} 1.253,173 62 Roy Castle Lung Cancer Foundation Note$ to th• Con$olldat¢d A¢¢ounts for th• yoar ¢nded 31 Oe¢ember 2023 42 Change In totsl fvnds over th• year, anatyswl by IrMlividu¥l funds {Qintinu¢d) Charity only Funds brought lorward Incom• Exponditur• 2022 as restated Funds Investment carried (loss•sl foThiard 2022 a$ Trstat8d Unrèstricted lunds.'_ unrest￿cled revenue funds 789,940 2.266,267 12,330.0641 180,952) 645,191 Total unr•strlct8d funds 789,940 2.266,267 12.330,0641 180,9521 645.191 RCFRe5tricted funds.". Research- GLCC Research- others 290,548 360,560 333.045 171.529 {340.7O01 1109.6561 310,408 394,918 Total restrlcted funds 623,593 532,089 14SO,3561 705.326 Total Charity Funds 1,413,533 2,798,356 12.780.420) 180.9521 1,350,517 43 The purposes forwhich thè funds as detail•d in notè 42 arn h•ld by th• chartty arÈ.'- Unrestri¢¢•d funds... Unrestricted revenue funds These funds are held for the m￿tIng the general objectives of the chanty. and to provide reserves for future activities, and subject to charity legislation, are free from all restrictions on their use Restricted lunds... Sundry RCF Restricted Rese These funds a￿ held for meeting specific objectives of the charty as spwfied by the donor. and to provide reserves for future suitable activities subjecl lo charity leg151ation and subject to the restrictions placed on them by individual donors, in P8rticAJlar to fund lung cancer research for individuals. GLCC These fund5 are held for rneeting specific objectives of the harity as 5peufied by Ihe dongr. and to provide reserves for future suitable actwitiÈS subjÈettts charity legislatTron and subject lo the reStriCt￿n5 placed on them by individual donors. in particular to fund lung cancer research ft>r individuals. Boehringer Ingleheim Awareness Project To lung Garvr awarene55 for Indiv￿ua1s. Cut Films Restricted Reserves To stimuLate discussion an￿)ngSt young pÈtsple about the Issue of smoktng. 63 Roy Castle Lung Cancer Foundation Notss to the Consolidated Accounts for th• year ended 31 December 2023 Group Charity 44 Flnancial instrurnents 2023 2022 2023 2022 Carrying amount of financial assets measured at falr value through in¢ome and expendilure Listed investments 669,783 873.367 669,783 873.387 4S Ultimate controlling party The Roy Castle Lung Cancer Foundation is the uttimate corrtrolling party and is underthe control of its legal members There is no one Individual controlling party. 11 Is ltre 5malle5t and largest entity for which consolidated aecounls are prepare